Matches in Wikidata for { <http://www.wikidata.org/entity/Q96617458> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q96617458 description "article scientifique publié en 2020" @default.
- Q96617458 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96617458 description "scientific article published on 20 June 2020" @default.
- Q96617458 description "wetenschappelijk artikel" @default.
- Q96617458 description "наукова стаття, опублікована 20 червня 2020" @default.
- Q96617458 name "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 name "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 type Item @default.
- Q96617458 label "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 label "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 prefLabel "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 prefLabel "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 P1433 Q96617458-15AE310B-F670-4683-BF09-74D94814B6B6 @default.
- Q96617458 P1476 Q96617458-DB8FBD9B-CE8C-426C-B4CA-DC4F50631937 @default.
- Q96617458 P2093 Q96617458-0586F2C9-87A6-4097-A4AF-E83118DDE990 @default.
- Q96617458 P2093 Q96617458-07DDFB20-0A4D-49D4-8374-2C4C0A7088B1 @default.
- Q96617458 P2093 Q96617458-155FED58-FD93-48E4-BD9E-5A4258BEC3E6 @default.
- Q96617458 P2093 Q96617458-1EC9A6D7-7E1A-4AAF-BF9C-347E8D2F3FD0 @default.
- Q96617458 P2093 Q96617458-20AC961B-3FC1-40E3-9FF7-E55CF52FA197 @default.
- Q96617458 P2093 Q96617458-47C7D571-FC42-4E9E-817F-DFD8DBE1C2BD @default.
- Q96617458 P2093 Q96617458-8692DB74-822C-47BC-800A-05E2A0B31FBF @default.
- Q96617458 P2093 Q96617458-8C8B44DB-F644-4E11-B1B0-914C457ACBC0 @default.
- Q96617458 P2093 Q96617458-993A9E21-96BD-48B6-9F16-E2CFC6DA318F @default.
- Q96617458 P2093 Q96617458-CD3755E4-D81D-45CB-87AB-17C934E4A73D @default.
- Q96617458 P2093 Q96617458-D306D23A-F8FA-4CC7-9228-7A4901A98DDE @default.
- Q96617458 P2093 Q96617458-F37C9D25-7A84-4F88-8149-CC821FAFC2F7 @default.
- Q96617458 P2093 Q96617458-FB48C529-BD2F-4E7B-9CEB-D7E328068E74 @default.
- Q96617458 P31 Q96617458-9D3CEB3D-FC01-40BE-8038-12481DBB07B9 @default.
- Q96617458 P356 Q96617458-A3D281E6-A56E-4732-B065-13612100DD73 @default.
- Q96617458 P50 Q96617458-42DE5F66-AFBD-4484-AA0B-CACCCA2233CC @default.
- Q96617458 P577 Q96617458-BCB4FD41-4A65-40E9-B365-4553928E7EFE @default.
- Q96617458 P698 Q96617458-871B7790-9E02-485A-B4AB-13B68D43C37B @default.
- Q96617458 P921 Q96617458-1F70753E-EB07-447F-91CC-7F854A6AE80A @default.
- Q96617458 P921 Q96617458-34FADC23-13B8-467B-A947-9CBC9CA4DC89 @default.
- Q96617458 P921 Q96617458-F81B7855-2886-45BD-8988-3F7ABF96D83F @default.
- Q96617458 P932 Q96617458-CF5C6E68-C464-40E4-8043-5F59873FD018 @default.
- Q96617458 P356 S10549-020-05728-W @default.
- Q96617458 P698 32564260 @default.
- Q96617458 P1433 Q326085 @default.
- Q96617458 P1476 "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study" @default.
- Q96617458 P2093 "Eleonora Restuccia" @default.
- Q96617458 P2093 "Guiyuan Lei" @default.
- Q96617458 P2093 "Hong Zhang" @default.
- Q96617458 P2093 "Hong Zheng" @default.
- Q96617458 P2093 "Huiping Li" @default.
- Q96617458 P2093 "Jifeng Feng" @default.
- Q96617458 P2093 "Qiao Li" @default.
- Q96617458 P2093 "Qingyuan Zhang" @default.
- Q96617458 P2093 "Tao Sun" @default.
- Q96617458 P2093 "Wei Li" @default.
- Q96617458 P2093 "Xiaojia Wang" @default.
- Q96617458 P2093 "Yongmei Yin" @default.
- Q96617458 P2093 "Zhimin Shao" @default.
- Q96617458 P31 Q13442814 @default.
- Q96617458 P356 "10.1007/S10549-020-05728-W" @default.
- Q96617458 P50 Q88164875 @default.
- Q96617458 P577 "2020-06-20T00:00:00Z" @default.
- Q96617458 P698 "32564260" @default.
- Q96617458 P921 Q12859063 @default.
- Q96617458 P921 Q412616 @default.
- Q96617458 P921 Q420436 @default.
- Q96617458 P932 "7320929" @default.